<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">We have formulated a treatment protocol based on patient characteristics, phase of illness, and disease severity using antivirals, immunomodulators, and immunosuppressive agents. These protocols are based on 
 <italic>inÂ vitro</italic> antiviral effects and empirical observations in other countries and are listed in the 
 <xref rid="appsec1" ref-type="sec">Supplementary Appendix S1</xref>. A recent trial did not show efficacy of lopinavir-ritonavir in severe COVID-19 infection, although with the limitations mentioned previously; of note, data on the role of such approach on subgroups such as patients receiving hemodialysis and who underwent transplantation are still lacking. Our proposed therapeutic management plan for patients receiving hemodialysis and who underwent transplantation with a SARS-CoV-2 infection can be found in the 
 <xref rid="appsec1" ref-type="sec">Supplementary Appendix S1</xref>. We also provide further considerations for diagnosis and treatment of these patients in the 
 <xref rid="appsec2" ref-type="fn">Supplementary Appendix S2</xref>.
</p>
